Literature DB >> 22659839

Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis.

Sangeeta Khanna1, Aseem Sharma, Julie Huecker, Mae Gordon, Robert T Naismith, Gregory P Van Stavern.   

Abstract

BACKGROUND: Patients with neuromyelitis optica (NMO) and multiple sclerosis (MS) both can present with acute optic neuritis (ON), while differing considerably in their prognosis and management. The clinical course, serologic testing results, and brain and spinal cord imaging of these diseases have been well documented. The purpose of this study was to look systematically for any differences in the imaging appearance of the optic nerve in NMO and MS-related ON.
METHODS: Magnetic resonance imaging (MRI) of brain and orbits obtained within 6 weeks of acute ON in patients with securely diagnosed NMO (n = 6) and MS (n = 11) were retrospectively analyzed by a neuroradiologist masked to the clinical diagnosis. Standardized scoring system was used to assess and analyze the extent and nature of optic pathway involvement.
RESULTS: No significant differences were observed in the presence, degree, or the type of signal alteration and contrast enhancement of the affected nerve segments between NMO and MS groups. There was a trend toward more posterior involvement of the optic nerve in the NMO group with chiasmatic enhancement exclusively seen in NMO patients.
CONCLUSION: We found a higher propensity of NMO-related ON to affect more posterior parts of the optic nerve, including chiasm, and have simultaneous bilateral disease. Further study with larger sample sizes is needed.

Entities:  

Mesh:

Year:  2012        PMID: 22659839     DOI: 10.1097/WNO.0b013e318254c62d

Source DB:  PubMed          Journal:  J Neuroophthalmol        ISSN: 1070-8022            Impact factor:   3.042


  33 in total

Review 1.  Current understanding of the epidemiologic and clinical characteristics of optic neuritis.

Authors:  Masanori Nakazawa; Hitoshi Ishikawa; Taiji Sakamoto
Journal:  Jpn J Ophthalmol       Date:  2021-05-22       Impact factor: 2.447

2.  Magnetic resonance imaging findings in giant cell arteritis.

Authors:  N M D'Souza; M L Morgan; S J Almarzouqi; A G Lee
Journal:  Eye (Lond)       Date:  2016-02-26       Impact factor: 3.775

3.  Acute optic neuritis with diffusion restriction on MRI.

Authors:  Wei-I Lee; Lauren Giles; Nicholas Crump
Journal:  BMJ Case Rep       Date:  2016-09-21

Review 4.  Acute onset blindness: a case of optic neuritis and review of childhood optic neuritis.

Authors:  Sithara Ramdas; Danny Morrison; Michael Absoud; Ming Lim
Journal:  BMJ Case Rep       Date:  2016-10-04

5.  MRI differences between MOG antibody disease and AQP4 NMOSD.

Authors:  Sara Salama; Majid Khan; Amirali Shanechi; Michael Levy; Izlem Izbudak
Journal:  Mult Scler       Date:  2020-01-15       Impact factor: 6.312

6.  Radiological characteristics of myelin oligodendrocyte glycoprotein antibody disease.

Authors:  Sara Salama; Majid Khan; Michael Levy; Izlem Izbudak
Journal:  Mult Scler Relat Disord       Date:  2019-01-10       Impact factor: 4.339

7.  First-ever optic neuritis: distinguishing subsequent neuromyelitis optica from multiple sclerosis.

Authors:  Young-Min Lim; So Young Pyun; Hyun Taek Lim; In Hye Jeong; Kwang-Kuk Kim
Journal:  Neurol Sci       Date:  2014-02-01       Impact factor: 3.307

8.  Visualization of inflammation and demyelination in 2D2 transgenic mice with rodent MRI.

Authors:  Jordan C Bell; Qingwei Liu; Yan Gan; Qiang Liu; Yaou Liu; Fu-Dong Shi; Gregory H Turner
Journal:  J Neuroimmunol       Date:  2013-09-18       Impact factor: 3.478

Review 9.  Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica.

Authors:  Jeffrey L Bennett
Journal:  J Neuroophthalmol       Date:  2016-09       Impact factor: 3.042

Review 10.  What do we know about brain contrast enhancement patterns in neuromyelitis optica?

Authors:  Yeliz Pekcevik; Gunes Orman; In Ho Lee; Maureen A Mealy; Michael Levy; Izlem Izbudak
Journal:  Clin Imaging       Date:  2015-07-26       Impact factor: 1.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.